The DOI matches its Crossref record; 186 of the 186 references it cites were found in a registry or an index.
Signal Transducer and Activator of Transcription (STATs) Proteins in Cancer and Inflammation: Functions and Therapeutic Implication
Open accessAbstract
Signal Transducer and Activator of Transcription (STAT) pathway is connected upstream with Janus kinases (JAK) family protein and capable of integrating inputs from different signaling pathways. Each family member plays unique functions in signal transduction and crucial in mediating cellular responses to different kind of cytokines. STAT family members notably STAT3 and STAT5 have been involved in cancer progression whereas STAT1 plays opposite role by suppressing tumor growth. Persistent STAT3/5 activation is known to promote chronic inflammation, which increases susceptibility of healthy cells to carcinogenesis. Here, we review the role of STATs in cancers and inflammation while discussing current therapeutic implications in different cancers and test models, especially the delivery of STAT3/5 targeting siRNA using nanoparticulate delivery system.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mantovani, A., Allavena, P., Sica, A., & Balkwill, F. (2008) · Nature · doi:10.1038/nature07205 · Cited by 11,399
Exosomes: composition, biogenesis and function
Théry, C., Zitvogel, L., & Amigorena, S. (2002) · Nature Reviews Immunology · doi:10.1038/nri855 · Cited by 5,346
Mdm2 promotes the rapid degradation of p53
Haupt, Y., Maya, R., Kazaz, A., & Oren, M. (1997) · Nature · doi:10.1038/387296a0 · Cited by 4,506 · cited 1×
“Mdm2 protein promotes degradation of the p53 protein by ubiquitination (93), is downregulated by STAT1 (91).”
BackgroundDarnell, J. E. (1997) · Science · doi:10.1126/science.277.5332.1630 · Cited by 3,979
HOW CELLS RESPOND TO INTERFERONS
Stark, G. R., Kerr, I. M., Williams, B. R. G., Silverman, R. H., & Schreiber, R. D. (1998) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.67.1.227 · Cited by 3,932
The p53 tumour suppressor gene
Levine, A. J., Momand, J., & Finlay, C. A. (1991) · Nature · doi:10.1038/351453a0 · Cited by 3,788
NF-κB: linking inflammation and immunity to cancer development and progression
Karin, M., & Greten, F. R. (2005) · Nature Reviews Immunology · doi:10.1038/nri1703 · Cited by 3,085
IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity
Shankaran, V., Ikeda, H., Bruce, A. T., White, J. M., Swanson, P. E., Old, L. J., & Schreiber, R. D. (2001) · Nature · doi:10.1038/35074122 · Cited by 2,896
Bromberg, J. F., Wrzeszczynska, M. H., Devgan, G., Zhao, Y., Pestell, R. G., Albanese, C., & Darnell, J. E. (1999) · Cell · doi:10.1016/s0092-8674(00)81959-5 · Cited by 2,790
Toxicity of cationic lipids and cationic polymers in gene delivery
Lv, H., Zhang, S., Wang, B., Cui, S., & Yan, J. (2006) · Journal of Controlled Release · doi:10.1016/j.jconrel.2006.04.014 · Cited by 2,286
The STATs of cancer — new molecular targets come of age
Yu, H., & Jove, R. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1275 · Cited by 2,278
Grivennikov, S., Karin, E., Terzic, J., Mucida, D., Yu, G.-Y., Vallabhapurapu, S., Scheller, J., Rose-John, S., Cheroutre, H., Eckmann, L., et al. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.01.001 · Cited by 2,155
Zhong, Z., Wen, Z., & Darnell, J. E. (1994) · Science · doi:10.1126/science.8140422 · Cited by 2,070
JAKS AND STATS: Biological Implications
Leonard, W. J., & O'Shea, J. J. (1998) · Annual Review of Immunology · doi:10.1146/annurev.immunol.16.1.293 · Cited by 1,804
Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment
Yu, H., Kortylewski, M., & Pardoll, D. (2007) · Nature Reviews Immunology · doi:10.1038/nri1995 · Cited by 1,804
Bowman, T., Garcia, R., Turkson, J., & Jove, R. (2000) · Oncogene · doi:10.1038/sj.onc.1203527 · Cited by 1,743
Catlett-Falcone, R., Landowski, T. H., Oshiro, M. M., Turkson, J., Levitzki, A., Savino, R., Ciliberto, G., Moscinski, L., Fernández-Luna, J. L., Nuñez, G., et al. (1999) · Immunity · doi:10.1016/s1074-7613(00)80011-4 · Cited by 1,638
Zhang, H., Freitas, D., Kim, H. S., Fabijanic, K., Li, Z., Chen, H., Mark, M. T., Molina, H., Martin, A. B., Bojmar, L., et al. (2018) · Nature Cell Biology · doi:10.1038/s41556-018-0040-4 · Cited by 1,613
Short hairpin RNAs (shRNAs) induce sequence-specific silencing in mammalian cells
Paddison, P. J., Caudy, A. A., Bernstein, E., Hannon, G. J., & Conklin, D. S. (2002) · Genes & Development · doi:10.1101/gad.981002 · Cited by 1,552
Demonstration of an interferon γ-dependent tumor surveillance system in immunocompetent mice
Kaplan, D. H., Shankaran, V., Dighe, A. S., Stockert, E., Aguet, M., Old, L. J., & Schreiber, R. D. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.13.7556 · Cited by 1,465
Interfering with disease: a progress report on siRNA-based therapeutics
de Fougerolles, A., Vornlocher, H.-P., Maraganore, J., & Lieberman, J. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2310 · Cited by 1,203
Hirano, T., Ishihara, K., & Hibi, M. (2000) · Oncogene · doi:10.1038/sj.onc.1203551 · Cited by 1,190
Buettner, R., Mora, L. B., & Jove, R. (2002) · PubMed · Cited by 1,185
Janus kinases in immune cell signaling
Ghoreschi, K., Laurence, A., & O’Shea, J. J. (2009) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00754.x · Cited by 1,149 · cited 1×
“In comparison with other JAK family members which are ubiquitously expressed in mammals, JAK3 is predominantly expressed in hematopoietic cells and is highly regulated with cell development and activation (113, 114).”
BackgroundJAK and STAT Signaling Molecules in Immunoregulation and Immune-Mediated Disease
O'Shea, J. J., & Plenge, R. (2012) · Immunity · doi:10.1016/j.immuni.2012.03.014 · Cited by 1,138
p53-dependent and independent expression of p21 during cell growth, differentiation, and DNA damage.
Macleod, K. F., Sherry, N., Hannon, G., Beach, D., Tokino, T., Kinzler, K., Vogelstein, B., & Jacks, T. (1995) · Genes & Development · doi:10.1101/gad.9.8.935 · Cited by 1,119
Is NF-κB a good target for cancer therapy? Hopes and pitfalls
Baud, V., & Karin, M. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2781 · Cited by 1,061
Causal Relationship between the Loss of RUNX3 Expression and Gastric Cancer
Li, Q.-L., Ito, K., Sakakura, C., Fukamachi, H., Inoue, K.-I., Chi, X.-Z., Lee, K.-Y., Nomura, S., Lee, C.-W., Han, S.-B., et al. (2002) · Cell · doi:10.1016/s0092-8674(02)00690-6 · Cited by 1,028
FDA-approved small-molecule kinase inhibitors
Wu, P., Nielsen, T. E., & Clausen, M. H. (2015) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2015.04.005 · Cited by 1,013
Bollrath, J., Phesse, T. J., von Burstin, V. A., Putoczki, T., Bennecke, M., Bateman, T., Nebelsiek, T., Lundgren-May, T., Canli, Ö., Schwitalla, S., et al. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.01.002 · Cited by 946
Synergistic Signaling in Fetal Brain by STAT3-Smad1 Complex Bridged by p300
Nakashima, K., Yanagisawa, M., Arakawa, H., Kimura, N., Hisatsune, T., Kawabata, M., Miyazono, K., & Taga, T. (1999) · Science · doi:10.1126/science.284.5413.479 · Cited by 865
Paracrine and Autocrine Signals Induce and Maintain Mesenchymal and Stem Cell States in the Breast
Scheel, C., Eaton, E. N., Li, S. H.-J., Chaffer, C. L., Reinhardt, F., Kah, K.-J., Bell, G., Guo, W., Rubin, J., Richardson, A. L., et al. (2011) · Cell · doi:10.1016/j.cell.2011.04.029 · Cited by 858
Inhibition of transforming growth factor-β/SMAD signalling by the interferon-γ/STAT pathway
Ulloa, L., Doody, J., & Massagué, J. (1999) · Nature · doi:10.1038/17826 · Cited by 812
Garcia, R., Bowman, T. L., Niu, G., Yu, H., Minton, S., Muro-Cacho, C. A., Cox, C. E., Falcone, R., Fairclough, R., Parsons, S., et al. (2001) · Oncogene · doi:10.1038/sj.onc.1204349 · Cited by 756
The Stat family in cytokine signaling
Ihle, J. N. (2001) · Current Opinion in Cell Biology · doi:10.1016/s0955-0674(00)00199-x · Cited by 713
Chin, Y. E., Kitagawa, M., Su, W.-C. S., You, Z.-H., Iwamoto, Y., & Fu, X.-Y. (1996) · Science · doi:10.1126/science.272.5262.719 · Cited by 696
Persistently Activated Stat3 Maintains Constitutive NF-κB Activity in Tumors
Lee, H., Herrmann, A., Deng, J.-H., Kujawski, M., Niu, G., Li, Z., Forman, S., Jove, R., Pardoll, D. M., & Yu, H. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.02.015 · Cited by 683
Nuclear factor-κB and inhibitor of κB kinase pathways in oncogenic initiation and progression
Bassères, D. S., & Baldwin, A. S. (2006) · Oncogene · doi:10.1038/sj.onc.1209942 · Cited by 667
Gao, S. P., Mark, K. G., Leslie, K., Pao, W., Motoi, N., Gerald, W. L., Travis, W. D., Bornmann, W., Veach, D., Clarkson, B., et al. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31871 · Cited by 666
STAT proteins: novel molecular targets for cancer drug discovery
Turkson, J., & Jove, R. (2000) · Oncogene · doi:10.1038/sj.onc.1204086 · Cited by 643
Targeting the STAT3 signaling pathway in cancer: Role of synthetic and natural inhibitors
Siveen, K. S., Sikka, S., Surana, R., Dai, X., Zhang, J., Kumar, A. P., Tan, B. K. H., Sethi, G., & Bishayee, A. (2014) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2013.12.005 · Cited by 634
Self-citationYang, J., Liao, X., Agarwal, M. K., Barnes, L., Auron, P. E., & Stark, G. R. (2007) · Genes & Development · doi:10.1101/gad.1553707 · Cited by 611
The emerging safety profile of JAK inhibitors in rheumatic disease
Winthrop, K. L. (2017) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2017.23 · Cited by 590
Ogura, H., Murakami, M., Okuyama, Y., Tsuruoka, M., Kitabayashi, C., Kanamoto, M., Nishihara, M., Iwakura, Y., & Hirano, T. (2008) · Immunity · doi:10.1016/j.immuni.2008.07.018 · Cited by 564
Bharti, A. C., Donato, N., & Aggarwal, B. B. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.171.7.3863 · Cited by 508
Grandis, J. R., Drenning, S. D., Chakraborty, A., Zhou, M. Y., Zeng, Q., Pitt, A. S., & Tweardy, D. J. (1998) · Journal of Clinical Investigation · doi:10.1172/jci3785 · Cited by 507
Haura, E. B., Turkson, J., & Jove, R. (2005) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0195 · Cited by 430
siRNA Delivery Strategies: A Comprehensive Review of Recent Developments
Tatiparti, K., Sau, S., Kashaw, S., & Iyer, A. (2017) · Nanomaterials · doi:10.3390/nano7040077 · Cited by 429
Bromberg, J. F., Horvath, C. M., Wen, Z., Schreiber, R. D., & Darnell, J. E. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.15.7673 · Cited by 422
Cationic lipids and polymers mediated vectors for delivery of siRNA
Zhang, S., Zhao, B., Jiang, H., Wang, B., & Ma, B. (2007) · Journal of Controlled Release · doi:10.1016/j.jconrel.2007.07.016 · Cited by 421
Role of STATs as downstream signal transducers in Src family kinase-mediated tumorigenesis
Silva, C. M. (2004) · Oncogene · doi:10.1038/sj.onc.1208159 · Cited by 403
AGGARWAL, B. B., SETHI, G., AHN, K. S., SANDUR, S. K., PANDEY, M. K., KUNNUMAKKARA, A. B., SUNG, B., & ICHIKAWA, H. (2006) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1378.063 · Cited by 398
Self-citationRole of Stat3 in Regulating p53 Expression and Function
Niu, G., Wright, K. L., Ma, Y., Wright, G. M., Huang, M., Irby, R., Briggs, J., Karras, J., Cress, W. D., Pardoll, D., et al. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.17.7432-7440.2005 · Cited by 392
Interpretation of cytokine signaling through the transcription factors STAT5A and STAT5B
Hennighausen, L., & Robinson, G. W. (2008) · Genes & Development · doi:10.1101/gad.1643908 · Cited by 356
Ernst, M., Najdovska, M., Grail, D., Lundgren-May, T., Buchert, M., Tye, H., Matthews, V. B., Armes, J., Bhathal, P. S., Hughes, N. R., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci34944 · Cited by 350
Wen, Z. (1997) · Nucleic Acids Research · doi:10.1093/nar/25.11.2062 · Cited by 325
Oncogenic potential of the RUNX gene family: ‘Overview’
Ito, Y. (2004) · Oncogene · doi:10.1038/sj.onc.1207755 · Cited by 316
Shin, D.-S., Kim, H.-N., Shin, K. D., Yoon, Y. J., Kim, S.-J., Han, D. C., & Kwon, B.-M. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2575 · Cited by 309
Xiong, H., Hong, J., Du, W., Lin, Y.-W., Ren, L.-L., Wang, Y.-C., Su, W.-Y., Wang, J.-L., Cui, Y., Wang, Z.-H., et al. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.295964 · Cited by 307
Stat5 Is Essential for the Myelo- and Lymphoproliferative Disease Induced by TEL/JAK2
Schwaller, J., Parganas, E., Wang, D., Cain, D., Aster, J. C., Williams, I. R., Lee, C.-K., Gerthner, R., Kitamura, T., Frantsve, J., et al. (2000) · Molecular Cell · doi:10.1016/s1097-2765(00)00067-8 · Cited by 303
Regulation of STAT‐dependent pathways by growth factors and cytokines
Leaman, D. W., Leung, S., Li, X., & Stark, G. R. (1996) · The FASEB Journal · doi:10.1096/fasebj.10.14.9002549 · Cited by 297
Genomic views of STAT function in CD4+ T helper cell differentiation
O'Shea, J. J., Lahesmaa, R., Vahedi, G., Laurence, A., & Kanno, Y. (2011) · Nature Reviews Immunology · doi:10.1038/nri2958 · Cited by 295
STAT proteins as novel targets for cancer drug discovery
Turkson, J. (2004) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.8.5.409 · Cited by 295
The regulation of inflammation by interferons and their STATs
Rauch, I., Müller, M., & Decker, T. (2013) · JAK-STAT · doi:10.4161/jkst.23820 · Cited by 281
Nelson, E. A., Walker, S. R., Weisberg, E., Bar-Natan, M., Barrett, R., Gashin, L. B., Terrell, S., Klitgaard, J. L., Santo, L., Addorio, M. R., et al. (2011) · Blood · doi:10.1182/blood-2009-11-255232 · Cited by 280
Subramaniam, A., Shanmugam, M. K., Perumal, E., Li, F., Nachiyappan, A., Dai, X., Swamy, S. N., Ahn, K. S., Kumar, A. P., Tan, B. K. H., et al. (2013) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2012.10.002 · Cited by 278
Self-citationTargeting Stat3 in cancer therapy
Jing, N., & Tweardy, D. J. (2005) · Anti-Cancer Drugs · doi:10.1097/00001813-200507000-00002 · Cited by 278
Lou, W., Ni, Z., Dyer, K., Tweardy, D. J., & Gao, A. C. (2000) · The Prostate · doi:10.1002/(sici)1097-0045(20000215)42:3<239::aid-pros10>3.0.co;2-g · Cited by 278
Kim, S., Koga, T., Isobe, M., Kern, B. E., Yokochi, T., Chin, Y. E., Karsenty, G., Taniguchi, T., & Takayanagi, H. (2003) · Genes & Development · doi:10.1101/gad.1119303 · Cited by 278
Point mutations in the RUNX1/AML1 gene: another actor in RUNX leukemia
Osato, M. (2004) · Oncogene · doi:10.1038/sj.onc.1207779 · Cited by 268
Targeting transcription factor STAT3 for cancer prevention and therapy
Chai, E. Z. P., Shanmugam, M. K., Arfuso, F., Dharmarajan, A., Wang, C., Kumar, A. P., Samy, R. P., Lim, L. H. K., Wang, L., Goh, B. C., et al. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2015.10.004 · Cited by 263
Self-citationWingelhofer, B., Neubauer, H. A., Valent, P., Han, X., Constantinescu, S. N., Gunning, P. T., Müller, M., & Moriggl, R. (2018) · Leukemia · doi:10.1038/s41375-018-0117-x · Cited by 243
Ito, K., Liu, Q., Salto-Tellez, M., Yano, T., Tada, K., Ida, H., Huang, C., Shah, N., Inoue, M., Rajnakova, A., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0743 · Cited by 237
STAT-1 Interacts with p53 to Enhance DNA Damage-induced Apoptosis
Townsend, P. A., Scarabelli, T. M., Davidson, S. M., Knight, R. A., Latchman, D. S., & Stephanou, A. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m302637200 · Cited by 234
The role of STATs in myeloid differentiation and leukemia
Coffer, P. J., Koenderman, L., & de Groot, R. P. (2000) · Oncogene · doi:10.1038/sj.onc.1203479 · Cited by 226
Do STAT3 inhibitors have potential in the future for cancer therapy?
Wong, A. L. A., Hirpara, J. L., Pervaiz, S., Eu, J.-Q., Sethi, G., & Goh, B.-C. (2017) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2017.1351941 · Cited by 225
Self-citationShahzad, M. M. K., Mangala, L. S., Han, H. D., Lu, C., Bottsford-Miller, J., Nishimura, M., Mora, E. M., Lee, J.-W., Stone, R. L., Pecot, C. V., et al. (2011) · Neoplasia · doi:10.1593/neo.101372 · Cited by 221
Knockdown of STAT3 expression by RNAi induces apoptosis in astrocytoma cells
Konnikova, L., Kotecki, M., Kruger, M. M., & Cochran, B. H. (2003) · BMC Cancer · doi:10.1186/1471-2407-3-23 · Cited by 217
Terminal osteoblast differentiation, mediated by runx2 and p27 KIP1, is disrupted in osteosarcoma
Thomas, D. M., Johnson, S. A., Sims, N. A., Trivett, M. K., Slavin, J. L., Rubin, B. P., Waring, P., McArthur, G. A., Walkley, C. R., Holloway, A. J., et al. (2004) · The Journal of Cell Biology · doi:10.1083/jcb.200409187 · Cited by 208
STAT signaling in the pathogenesis and treatment of leukemias
Lin, T. S., Mahajan, S., & Frank, D. A. (2000) · Oncogene · doi:10.1038/sj.onc.1203486 · Cited by 205
Li, F., Fernandez, P. P., Rajendran, P., Hui, K. M., & Sethi, G. (2010) · Cancer Letters · doi:10.1016/j.canlet.2009.12.003 · Cited by 201
Self-citationOu, W., Thapa, R. K., Jiang, L., Soe, Z. C., Gautam, M., Chang, J.-H., Jeong, J.-H., Ku, S. K., Choi, H.-G., Yong, C. S., et al. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.05.018 · Cited by 200
Capsaicin Is a Novel Blocker of Constitutive and Interleukin-6–Inducible STAT3 Activation
Bhutani, M., Pathak, A. K., Nair, A. S., Kunnumakkara, A. B., Guha, S., Sethi, G., & Aggarwal, B. B. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2575 · Cited by 197
Self-citationRequirement of Stat3 signaling for HGF/SF-Met mediated tumorigenesis
Zhang, Y.-W., Wang, L.-M., Jove, R., & Vande Woude, G. F. (2002) · Oncogene · doi:10.1038/sj.onc.1205004 · Cited by 196
Kim, C., Lee, S.-G., Yang, W. M., Arfuso, F., Um, J.-Y., Kumar, A. P., Bian, J., Sethi, G., & Ahn, K. S. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.05.038 · Cited by 195
Self-citationSTAT inhibitors for cancer therapy
Furqan, M., Akinleye, A., Mukhi, N., Mittal, V., Chen, Y., & Liu, D. (2013) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-6-90 · Cited by 187
Coordinate regulation of cell growth and differentiation by TGF-β superfamily and Runx proteins
Miyazono, K., Maeda, S., & Imamura, T. (2004) · Oncogene · doi:10.1038/sj.onc.1207131 · Cited by 182
Arredondo, J., Chernyavsky, A. I., Jolkovsky, D. L., Pinkerton, K. E., & Grando, S. A. (2006) · The FASEB Journal · doi:10.1096/fj.06-6191com · Cited by 182
Baek, S. H., Ko, J.-H., Lee, H., Jung, J., Kong, M., Lee, J.-W., Lee, J., Chinnathambi, A., Zayed, M., Alharbi, S. A., et al. (2016) · Phytomedicine · doi:10.1016/j.phymed.2016.02.011 · Cited by 181
Self-citationLi, F., Shanmugam, M. K., Chen, L., Chatterjee, S., Basha, J., Kumar, A. P., Kundu, T. K., & Sethi, G. (2013) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-13-0070 · Cited by 180
Self-citationRani, A., & Murphy, J. J. (2016) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.2015.0054 · Cited by 173
Sethi, G., Chatterjee, S., Rajendran, P., Li, F., Shanmugam, M. K., Wong, K. F., Kumar, A. P., Senapati, P., Behera, A. K., Hui, K. M., et al. (2014) · Molecular Cancer · doi:10.1186/1476-4598-13-66 · Cited by 171
Self-citationLee, J. H., Kim, C., Sethi, G., & Ahn, K. S. (2015) · Oncotarget · doi:10.18632/oncotarget.3443 · Cited by 162
Self-citationSu, W., Su, W., Cheng, C., Shieh, & Yeh (2012) · International Journal of Nanomedicine · doi:10.2147/ijn.s33666 · Cited by 162
Polycation-based nanoparticle delivery of RNAi therapeutics: Adverse effects and solutions
Ballarín-González, B., & Howard, K. A. (2012) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.07.004 · Cited by 162
Addressing the problem of cationic lipid-mediated toxicity: The magnetoliposome model
Soenen, S. J. H., Brisson, A. R., & De Cuyper, M. (2009) · Biomaterials · doi:10.1016/j.biomaterials.2009.03.040 · Cited by 162
Zhang, J., Ahn, K. S., Kim, C., Shanmugam, M. K., Siveen, K. S., Arfuso, F., Samym, R. P., Deivasigamanim, A., Lim, L. H. K., Wang, L., et al. (2016) · Antioxidants & Redox Signaling · doi:10.1089/ars.2015.6418 · Cited by 162
Self-citationYano, T., Ito, K., Fukamachi, H., Chi, X.-Z., Wee, H.-J., Inoue, K.-I., Ida, H., Bouillet, P., Strasser, A., Bae, S.-C., et al. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.01926-05 · Cited by 161
Larmonier, N., Janikashvili, N., LaCasse, C. J., Larmonier, C. B., Cantrell, J., Situ, E., Lundeen, T., Bonnotte, B., & Katsanis, E. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.10.6955 · Cited by 160
Mohan, C. D., Bharathkumar, H., Bulusu, K. C., Pandey, V., Rangappa, S., Fuchs, J. E., Shanmugam, M. K., Dai, X., Li, F., Deivasigamani, A., et al. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.601104 · Cited by 159
Self-citationZhang, X., Tian, W., Cai, X., Wang, X., Dang, W., Tang, H., Cao, H., Wang, L., & Chen, T. (2013) · PLoS ONE · doi:10.1371/journal.pone.0065896 · Cited by 158
Rajendran, P., Li, F., Shanmugam, M. K., Kannaiyan, R., Goh, J. N., Wong, K. F., Wang, W., Khin, E., Tergaonkar, V., Kumar, A. P., et al. (2012) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-11-0420 · Cited by 158
Self-citationPharmacologic inhibition of STAT5 in acute myeloid leukemia
Wingelhofer, B., Maurer, B., Heyes, E. C., Cumaraswamy, A. A., Berger‐Becvar, A., de Araujo, E. D., Orlova, A., Freund, P., Ruge, F., Park, J., et al. (2018) · Leukemia · doi:10.1038/s41375-017-0005-9 · Cited by 157
Formulation and Delivery of siRNA by Oleic Acid and Stearic Acid Modified Polyethylenimine
Alshamsan, A., Haddadi, A., Incani, V., Samuel, J., Lavasanifar, A., & Uludağ, H. (2008) · Molecular Pharmaceutics · doi:10.1021/mp8000815 · Cited by 156
The Runx genes: lineage-specific oncogenes and tumor suppressors
Cameron, E. R., & Neil, J. C. (2004) · Oncogene · doi:10.1038/sj.onc.1207130 · Cited by 155
Shanmugam, M. K., Rajendran, P., Li, F., Nema, T., Vali, S., Abbasi, T., Kapoor, S., Sharma, A. K., Kumar, A. P., Ho, P. C., et al. (2011) · Journal of Molecular Medicine · doi:10.1007/s00109-011-0746-2 · Cited by 153
Self-citationSpecial delivery: targeted therapy with small RNAs
Peer, D., & Lieberman, J. (2011) · Gene Therapy · doi:10.1038/gt.2011.56 · Cited by 152
Stat5 promotes metastatic behavior of human prostate cancer cells in vitro and in vivo
Gu, L., Vogiatzi, P., Puhr, M., Dagvadorj, A., Lutz, J., Ryder, A., Addya, S., Fortina, P. M., Cooper, C. R., Leiby, B. E., et al. (2010) · Endocrine Related Cancer · doi:10.1677/erc-09-0328 · Cited by 146
Akhavan, D., Pourzia, A. L., Nourian, A. A., Williams, K. J., Nathanson, D. A., Babić, I., Villa, G. R., Tanaka, K., Nael, A., Yang, H., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0502 · Cited by 145
Ma, J., & Cao, X. (2005) · Cellular Signalling · doi:10.1016/j.cellsig.2005.06.016 · Cited by 144
Luo, Z., Wang, C., Yi, H., Li, P., Pan, H., Liu, L., Cai, L., & Ma, Y. (2014) · Biomaterials · doi:10.1016/j.biomaterials.2014.10.050 · Cited by 142
Lee, J. H., Chiang, S. Y., Nam, D., Chung, W., Lee, J., Na, Y.-S., Sethi, G., & Ahn, K. S. (2013) · Cancer Letters · doi:10.1016/j.canlet.2013.12.008 · Cited by 141
Self-citationYamashita, H., Xu, J., Erwin, R. A., Farrar, W. L., Kirken, R. A., & Rui, H. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.46.30218 · Cited by 140
Rajendran, P., Ong, T. H., Chen, L., Li, F., Shanmugam, M. K., Vali, S., Abbasi, T., Kapoor, S., Sharma, A. K., Kumar, A. P., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1123 · Cited by 140
Self-citationKannaiyan, R., Hay, H. S., Rajendran, P., Li, F., Shanmugam, M. K., Vali, S., Abbasi, T., Kapoor, S., Sharma, A. K., Kumar, A. P., et al. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01449.x · Cited by 138
Self-citationKim, C., Cho, S. K., Kapoor, S., Kumar, A., Vali, S., Abbasi, T., Kim, S., Sethi, G., & Ahn, K. S. (2013) · Molecular Carcinogenesis · doi:10.1002/mc.22035 · Cited by 138
Self-citationRajendran, P., Li, F., Manu, K., Shanmugam, M. K., Loo, S., Kumar, A., & Sethi, G. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.01187.x · Cited by 133
Self-citationArora, L., Kumar, A. P., Arfuso, F., Chng, W. J., & Sethi, G. (2018) · Cancers · doi:10.3390/cancers10090327 · Cited by 127
Self-citationCapsazepine inhibits JAK/STAT3 signaling, tumor growth, and cell survival in prostate cancer
Lee, J. H., Kim, C., Baek, S. H., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.10775 · Cited by 125
Yin, D., Li, Y., Lin, H., Guo, B., Du, Y., Li, X., Jia, H., Zhao, X., Tang, J., & Zhang, L. (2013) · Nanotechnology · doi:10.1088/0957-4484/24/10/105102 · Cited by 124
Konnikova, L., Simeone, M., Kruger, M. M., Kotecki, M., & Cochran, B. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0924 · Cited by 124
STAT3 Gene Silencing by Aptamer-siRNA Chimera as Selective Therapeutic for Glioblastoma
Esposito, C. L., Nuzzo, S., Catuogno, S., Romano, S., de Nigris, F., & de Franciscis, V. (2017) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2017.12.021 · Cited by 116
Xu, Y., & Lü, S. (2013) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2013.11.012 · Cited by 115
Surface modification of gold and quantum dot nanoparticles with chitosan for bioapplications
Tan, W. B., & Zhang, Y. (2005) · Journal of Biomedical Materials Research Part A · doi:10.1002/jbm.a.30410 · Cited by 115
Alshamsan, A., Hamdy, S. I., Samuel, J., El‐Kadi, A. O. S., Lavasanifar, A., & Uludağ, H. (2009) · Biomaterials · doi:10.1016/j.biomaterials.2009.11.003 · Cited by 114
Kazansky, A. V., Kabotyanski, E. B., Wyszomierski, S. L., Mancini, M. A., & Rosen, J. M. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.32.22484 · Cited by 113
Recent advances of siRNA delivery by nanoparticles
Yuan, X., Naguib, S., & Wu, Z. (2011) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2011.559223 · Cited by 113
Labala, S., Jose, A., Chawla, S. R., Khan, M. S., Bhatnagar, S., Kulkarni, O. P., & Venuganti, V. V. K. (2017) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2017.03.087 · Cited by 108
Metastatic bone disease: Role of transcription factors and future targets
Pratap, J., Lian, J. B., & Stein, G. S. (2010) · Bone · doi:10.1016/j.bone.2010.05.035 · Cited by 104
Sano, S., Chan, K. S., Kira, M., Kataoka, K., Takagi, S., Tarutani, M., Itami, S., Kiguchi, K., Yokoi, M., Sugasawa, K., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4359 · Cited by 103
Harnessing RNAi-based nanomedicines for therapeutic gene silencing in B-cell malignancies
Weinstein, S., Toker, I. A., Emmanuel, R., Ramishetti, S., Hazan‐Halevy, I., Rosenblum, D., Goldsmith, M., Avigdor, A., Benjamini, O., Bairey, O., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1519273113 · Cited by 97
Baran‐Marszak, F., Feuillard, J., Najjar, I., Clorennec, C. L., BÉCHET, J.-M., Dusanter‐Fourt, I., Bornkamm, G. W., Raphaël, M., & Fagard, R. (2004) · Blood · doi:10.1182/blood-2003-10-3508 · Cited by 94
Labala, S., Jose, A., & Venuganti, V. V. K. (2016) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2016.05.076 · Cited by 94
Liu, L., Liu, Y. L., Liu, G. X., Chen, X., Yang, K., Yang, Y., Xie, Q., Gan, H., Huang, X. L., & Gan, H. T. (2013) · International Immunopharmacology · doi:10.1016/j.intimp.2013.06.020 · Cited by 92
Melittin derived peptides for nanoparticle based siRNA transfection
Hou, K. K., Pan, H., Lanza, G. M., & Wickline, S. A. (2013) · Biomaterials · doi:10.1016/j.biomaterials.2013.01.037 · Cited by 91
Hung, W., & Elliott, B. E. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m010715200 · Cited by 88
Atiprimod blocks STAT3 phosphorylation and induces apoptosis in multiple myeloma cells
Amit-Vazina, M., Shishodia, S., Harris, D., Van, Q., Wang, M., Weber, D., Alexanian, R., Talpaz, M., Aggarwal, B. B., & Estrov, Z. E. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602637 · Cited by 86
Curcumin formulated in solid lipid nanoparticles has enhanced efficacy in Hodgkin's lymphoma in mice
Guorgui, J. G., Wang, R., Mattheolabakis, G., & Mackenzie, G. G. (2018) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2018.04.012 · Cited by 83
Shanmugam, M. K., Rajendran, P., Li, F., Kim, C., Sikka, S., Siveen, K. S., Kumar, A. P., Ahn, K. S., & Sethi, G. (2014) · Molecular Carcinogenesis · doi:10.1002/mc.22166 · Cited by 81
Self-citationZhang, J., Sikka, S., Siveen, K. S., Lee, J. H., Um, J., Kumar, A. P., Chinnathambi, A., Alharbi, S. A., Basappa, B., Rangappa, K. S., et al. (2016) · APOPTOSIS · doi:10.1007/s10495-016-1313-7 · Cited by 80
Self-citationGao, L., Xu, D.-Q., Wen, L., Zhang, X., Shao, Y., & Zhao, X. (2005) · Acta Pharmacologica Sinica · doi:10.1111/j.1745-7254.2005.00053.x · Cited by 77
Nanoparticle delivery of a peptide targeting EGFR signaling
Kim, S. K., & Huang, L. (2011) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.08.014 · Cited by 75
Stat3-siRNA induces Fas-mediated apoptosis in vitro and in vivo in breast cancer
Rao (2009) · International Journal of Oncology · doi:10.3892/ijo_00000249 · Cited by 75
Xiong, H., Su, W., Liang, Q., Zhang, Z., Chen, H., Du, W., Chen, Y., & Fang, J. (2009) · Laboratory Investigation · doi:10.1038/labinvest.2009.11 · Cited by 74
STAT-3 Inhibitors: State of the Art and New Horizons for Cancer Treatment
Lavecchia, A., Giovanni, C. D., & Novellino, E. (2011) · Current Medicinal Chemistry · doi:10.2174/092986711795843218 · Cited by 73
Baek, S., Lee, J., Kim, C., Ko, J., Ryu, S.-H., Lee, S., Yang, W. M., Um, J., Chinnathambi, A., Alharbi, S. A., et al. (2017) · Molecules · doi:10.3390/molecules22020276 · Cited by 73
Self-citationKim, S., Kim, C., Bae, H., Lee, J. H., Baek, S. H., Nam, D., Chung, W., Shim, B. S., Lee, S., Kim, S., et al. (2014) · Molecular Carcinogenesis · doi:10.1002/mc.22184 · Cited by 72
Self-citationLiu, Y., Fuchs, J. R., Li, C., & Lin, J. (2010) · Cell Cycle · doi:10.4161/cc.9.17.12946 · Cited by 72
Eradication of Acute Myeloid Leukemia with FLT3 Ligand–Targeted miR-150 Nanoparticles
Jiang, X., Bugno, J., Hu, C., Yang, Y., Herold, T., Qi, J., Chen, P., Gurbuxani, S. K., Arnovitz, S., Strong, J., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-2949 · Cited by 71
Park, S.-H., Yamashita, H., Rui, H., & Waxman, D. J. (2001) · Molecular Endocrinology · doi:10.1210/me.15.12.2157 · Cited by 69
Liao, D., Liu, Z., Wrasidlo, W., Chen, T., Luo, Y., Xiang, R., & Reisfeld, R. A. (2011) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2011.03.001 · Cited by 63
Choi, J. K., Kim, K. H., Park, H., Park, S. R., & Choi, B. H. (2010) · APOPTOSIS · doi:10.1007/s10495-010-0552-2 · Cited by 62
Ma, Y., Zhang, X., Xu, X., Shen, L., Yao, Y., Yang, Z., & Liu, P. (2015) · PLoS ONE · doi:10.1371/journal.pone.0124924 · Cited by 55
Efficient gene transfer into primary human natural killer cells by retroviral transduction.
Guvén, H., Konstantinidis, K., Alici, E., Aints, A., Abedi-Valugerdi, M., Christensson, B., Ljunggren, H., & Dilber, M. (2005) · Experimental Hematology · doi:10.1016/j.exphem.2005.07.006 · Cited by 55
IL-6 activates STAT5 in T cells
Tormo, A. J., Letellier, M.-C., Sharma, M., Elson, G., Crabé, S., & Gauchat, J. (2012) · Cytokine · doi:10.1016/j.cyto.2012.07.002 · Cited by 53
Das, J., Das, S., Paul, A., Samadder, A., Bhattacharyya, S. S., & Khuda‐Bukhsh, A. R. (2014) · Toxicology Letters · doi:10.1016/j.toxlet.2014.01.009 · Cited by 52
Signal Transducer and Activator of Transcription 3 - A Promising Target in Colitis-Associated Cancer
Pandurangan, A. K., & Esa, N. M. (2014) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2014.15.2.551 · Cited by 52
Essential functions of p21-activated kinase 1 in morphogenesis and differentiation of mammary glands
Wang, R., Vadlamudi, R. K., Bagheri‐Yarmand, R., Beuvink, I., Hynes, N. E., & Kumar, R. (2003) · The Journal of Cell Biology · doi:10.1083/jcb.200212066 · Cited by 51
Identification of a novel p53-dependent activation pathway of STAT1 by antitumour genotoxic agents
Youlyouz‐Marfak, I., Gachard, N., Clorennec, C. L., Najjar, I., Baran‐Marszak, F., Reminieras, L., May, E., Bornkamm, G. W., Fagard, R., & Feuillard, J. (2007) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4402270 · Cited by 50
STAT5-Interacting Proteins: A Synopsis of Proteins that Regulate STAT5 Activity
Able, A., Burrell, J. A., & Stephens, J. M. (2017) · Biology · doi:10.3390/biology6010020 · Cited by 50
Discovery of a highly selective JAK3 inhibitor for the treatment of rheumatoid arthritis
Pei, H., He, L., Shao, M., Yang, Z., Ran, Y., Li, D., Zhou, Y., Tang, M., Wang, T., Gong, Y., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-23569-y · Cited by 50
Molavi, O., Mahmud, A., Hamdy, S. I., Hung, R., Lai, R. L., Samuel, J., & Lavasanifar, A. (2009) · Molecular Pharmaceutics · doi:10.1021/mp900145g · Cited by 48
Zhang, W., Sun, H., Shi, X., Wang, H., Cui, C., Xiao, F., Wu, C.-T., Guo, X., & Wang, L. (2015) · Tumor Biology · doi:10.1007/s13277-015-4406-y · Cited by 44
Efficient shRNA delivery into B and T lymphoma cells using lentiviral vector-mediated transfer
Anastasov, N., Klier, M., Koch, I., Angermeier, D., Höfler, H., Fend, F., & Quintanilla‐Martinez, L. (2008) · Journal of Hematopathology · doi:10.1007/s12308-008-0020-x · Cited by 41
Emeagi, P. U., Maenhout, S. K., Dang, N., Heirman, C., Thielemans, K., & Breckpot, K. (2013) · Gene Therapy · doi:10.1038/gt.2013.35 · Cited by 39
Xu, X., Dong, Z., Li, Y., Yang, Y., Zeng, Y., Qu, X., & Kong, B. (2012) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2012.12.010 · Cited by 39
Rathore, R., Jain, J. P., Srivastava, A., Jachak, S. M., & Kumar, N. (2007) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2007.09.019 · Cited by 38
Kotmakçı, M., Çetintaş, V. B., & Kantarcı, A. G. (2017) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2017.04.034 · Cited by 36
STAT5 regulates glioma cell invasion by pathways dependent and independent of STAT5 DNA binding
Cao, S., Wang, C., Zheng, Q., Qiao, Y., Xu, K., Jiang, T., & Wu, A. (2010) · Neuroscience Letters · doi:10.1016/j.neulet.2010.10.028 · Cited by 31
Korin, E., Bejerano, T., & Cohen, S. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.10.001 · Cited by 31
Yang, G., Huang, C., Cao, J., Huang, K., Jiang, T., & Qiu, Z. (2009) · World Journal of Gastroenterology · doi:10.3748/wjg.15.3757 · Cited by 29
Najar, A. G., Pashaei‐Asl, R., Omidi, Y., Farajnia, S., & Nourazarian, A. (2013) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2013.14.1.495 · Cited by 29
Knockdown of STAT3 expression in SKOV3 cells by biodegradable siRNA–PLGA/CSO conjugate micelles
Zhao, Y., Zheng, C., Zhang, L., Chen, Y., Ye, Y., & Zhao, M. (2015) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2015.01.034 · Cited by 26
STAT3 inhibitor, cucurbitacin I, is a novel therapeutic agent for osteosarcoma
Oi, T., Asanuma, K., Matsumine, A., Matsubara, T., Nakamura, T., Iino, T., Asanuma, Y., Goto, M., Okuno, K., Kakimoto, T., et al. (2016) · International Journal of Oncology · doi:10.3892/ijo.2016.3757 · Cited by 25
Serine phosphorylation of Stat5 proteins in lymphocytes stimulated with IL-2
Xue, H. (2002) · International Immunology · doi:10.1093/intimm/dxf101 · Cited by 24
The Natural Chemopreventive Agent Sulforaphane Inhibits STAT5 Activity
Pinz, S., Unser, S., & Rascle, A. (2014) · PLoS ONE · doi:10.1371/journal.pone.0099391 · Cited by 23
Shi, K., Fang, Y., Gao, S., Yang, D., Bi, H., Xue, J., Lu, A., Li, Y., Ke, L., Lin, X., et al. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.04.023 · Cited by 22
Cui, J. T. (2011) · International Journal of Oncology · doi:10.3892/ijo.2011.1053 · Cited by 20
Forti, E., Kryukov, O., Elovic, E., Goldshtein, M., Korin, E., Margolis, G., Felder, S., Ruvinov, E., & Cohen, S. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.04.033 · Cited by 17
Kaido, T., Oe, H., & Imamura, M. (2004) · PubMed · Cited by 13
Changing the STATus quo in T helper cells
Stritesky, G. L., & Kaplan, M. H. (2011) · Transcription · doi:10.4161/trns.2.4.16614 · Cited by 10
Wheezing and itching: The requirement for STAT proteins in allergic inflammation
Glosson, N. L., Bruns, H. A., & Kaplan, M. H. (2012) · JAK-STAT · doi:10.4161/jkst.19086 · Cited by 9
Wang, X., Liu, P., Liu, H., Yang, W., Liu, Z., Zhuo, Z., & Gao, Y. (2012) · Cancer Gene Therapy · doi:10.1038/cgt.2012.65 · Cited by 9
Murone, M., Chessex, A. V., Attinger, A., Ramachandra, R. K., Shetty, S. J., Daginakatte, G., Sengupta, S., Marappan, S., Dhodheri, S., Rigotti, S., et al. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0974 · Cited by 8
Subramaniam, A., Shanmugam, M. K., Perumal, E., Li, F., Nachiyappan, A., Kumar, A. P., Tan, B. K. H., & Sethi, G. (2013) · Springer eBooks · doi:10.1007/978-81-322-1533-2_6 · Cited by 2
Self-citation
Cited by
Loh, C.-Y., Chai, J., Tang, T., Wong, W., Sethi, G., Shanmugam, M., Chong, P., & Looi, C. (2019) · Cells · doi:10.3390/cells8101118 · Cited by 1,315
Self-citationLiu, J., Han, X., Zhang, T., Tian, K., Li, Z., & Luo, F. (2023) · Journal of Hematology & Oncology · doi:10.1186/s13045-023-01512-7 · Cited by 660
Advances in Targeting ‘Undruggable’ transcription Factors With Small Molecules
Henley, M. J., & Koehler, A. N. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00199-0 · Cited by 409
Sharifi-Rad, J., Quispe, C., Imran, M., Rauf, A., Nadeem, M., Gondal, T. A., Ahmad, B., Atif, M., Mubarak, M. S., Sytar, O., et al. (2021) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2021/3268136 · Cited by 389
Hepatocellular carcinoma: signaling pathways and therapeutic advances
Zheng, J., Wang, S., Xia, L., Sun, Z., Chan, K. M., Bernards, R., Qin, W., Chen, J., Xia, Q., & Jin, H. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02075-w · Cited by 341
Metadata
- Authors
- Loh, C.-Y., Arya, A., Naema, A. F., Wong, W. F., Sethi, G., & Looi, C. Y.
- Venue
- Frontiers in Oncology
- Publisher
- Frontiers Media SA
- Published
- 2019-02-21
- Volume
- 9
- Pages
- 48-48
- ISSN
- 2234-943X (ISSN-L)
- OpenAlex
- W2917410143
- Cited by
- 348
- References
- 186
- FWCI
- 16.69
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.